Akeso and Summit Therapeutics disclosed updated data from the China-based Harmoni-6 trial for ivonescimab, a PD-1/VEGF bispecific antibody. Updated follow-up showed the progression-free survival (PFS) benefit narrowed, renewing scrutiny around the trial’s durability and differentiation. The reaction from the market and the clinical community is likely to center on the magnitude of the updated benefit versus the original readout and whether future datasets can re-establish statistical confidence. For developers, bispecific oncology programs are highly sensitive to follow-up maturity, particularly when endpoints guide regulatory strategy. The update comes at a time when developers in China are actively expanding global programs, so changes in PFS curves can influence partner interest, trial design decisions, and the feasibility of registrational pathways.